HomeAI · summaries
Storia in 2 fonti
Lupin gets USFDA tentative approval for prostate cancer treatment drug
Indian pharmaceutical giant Lupin Ltd has secured tentative approval from the US FDA for its generic enzalutamide tablets, a crucial treatment for advanced prostate cancer. This approval covers multiple strengths, including 40 mg, 80 mg, 120 mg, and 160 mg. The company's offering is bioequivalent to the reference drug, Xtandi, and aims to provide more flexible dosing options for patients and medical professionals.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
Lupin gets tentative US FDA nod for Enzalutamide tablets
Lupin receives tentative US FDA approval for Enzalutamide Tablets, offering new dosing options as a bioequivalent to Xtandi.
- ·
economictimes.indiatimes.com
Lupin gets USFDA tentative approval for prostate cancer treatment drug
Indian pharmaceutical giant Lupin Ltd has secured tentative approval from the US FDA for its generic enzalutamide tablets, a crucial treatment for advanced prostate cancer. This…